Attovia Therapeutics (ATTO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$4.88
- Estimate
- -$4.61
- Surprise
- -5.7%
- Revenue (period 2026-06-30)
- $450,000
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
Attovia Therapeutics (ATTO) reported a wider loss than forecast — adjusted EPS of -$4.88 against the -$4.61 estimate (a 5.7% shortfall).
Coverage in the report window
- Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday — benzinga, 2026-09-04
- Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K — benzinga, 2026-09-02
- Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30 — benzinga, 2026-08-31
Where TrendMatrix's rating stands now
TrendMatrix currently rates ATTO Sell at 5.6/10; no pre/post engine snapshot brackets this report.
0 of the last 1 quarters beat the estimate; this quarter's -5.7% surprise compares with a -5.7% four-quarter average. Next scheduled report: 2026-11-11.
What argues against it
- Quality below floor (3.0 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (21 sells, 0.84% of cap)
- Momentum score 4.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.16
- Price target
- $36.71
- Stop
- $16.89
- Upside to target
- +102.1%
- Reward-to-risk
- 6.8:1
Risk check: RSI 28 — a level conventionally read as oversold; trading volume is running 2.3× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-29 — shown for context, not personalized investment advice.
ATTO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $805.7M
- P/E (fwd)
- -7.4
- 52-week range
- $16.15–$28.00
- Off 52-week high
- 35.1%
- RSI (14)
- 28
- Volume vs avg
- 2.33×
- Score today
- 5.6/10